Noveratech L.L.C. — Department of Health and Human Services SBIR Phase I: 100

Description

DESCRIPTION provided by applicant This proposal is submitted in response to the new NIDDK announcement PA calling for development of methodologies or biomarkers to help understand the pathophysiology of T D type diabetes T D complications An estimated of the million diabetic patients in this country will develop diabetic foot ulcers DFU at some point in their lives DFU is the leading cause of non traumatic lower extremity amputations caused by non healing wounds Despite thousands of dressing products developed to treat chronic wounds none has proven effective for DFU As stated in the RFA a significant obstacle for progress in developing drugs for diabetic complications is the paucity of biomarkers and surrogate endpoints for measuring the initiation progression and response to treatments of diabetic complications Although many factors are involved in non healing DFU tissue ischemia is known to be a major factor contributing to poor wound healing Ischemia may not be the initiating factor for DFU because most ulcers start from a combination of neuropathy pressure loading and or trauma However tissue ischemia is the main cause that hinders healing Providing oxygen to chronic ulcers has not obtained stable results This is because oxygen is only one of the ingredients required for HEP production The specific aim of this phase I proposal is to explore the possibility of using high energy phosphate HEP contents as a biomarker to predict the progression and recurrence of diabetic ulcers We plan to use a diabetic animal wound model with and without ischemia to test the changes of HEP in these wounds along with the expression of several key factors known to be critical to wound healing such as vascular endothelial growth factors cytokines macrophages collagens and angiogenesis and correlated them to obtain a preliminary picture of the relationship between these factors and the haling of diabetic wounds The result may provide a preliminary indication whether the change of HEP content alone or along with other key factors will be better used to predict the likelihood of healing This is a difficult job but we already have a proof of concept PUBLIC HEALTH RELEVANCE A significant obstacle for progress in developing drugs for diabetic complications is the paucity of biomarkers and surrogate endpoints to measure the initiation progress and response to treatments for diabetic foot ulcers despite decades of research We have found that tissue high energy phosphate contents are severely reduced in human diabetic wounds and supplementation of high energy phosphate to diabetic wounds in animals resulted in enhanced healing along with up regulation of growth factors cytokines angiogenesis and macrophage accumulation and proliferation This phase I proposal will explore the possibility of using tissue high energy phosphate as a biomarker to predict the likelihood of healing along with the expression of growth factors cytokines macrophages and angiogenesis Our goal is to develop a biomarker which is low cost easy to use and accurate for diabetic foot ulcers